PE20201255A1 - Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos - Google Patents

Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos

Info

Publication number
PE20201255A1
PE20201255A1 PE2020000682A PE2020000682A PE20201255A1 PE 20201255 A1 PE20201255 A1 PE 20201255A1 PE 2020000682 A PE2020000682 A PE 2020000682A PE 2020000682 A PE2020000682 A PE 2020000682A PE 20201255 A1 PE20201255 A1 PE 20201255A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
antibody
antibodies
Prior art date
Application number
PE2020000682A
Other languages
English (en)
Inventor
Manoj Baburao Charati
Yoon-Chi Han
Madan Katragadda
Nicole Melissa Piche-Nicholas
Lawrence Nathan Tumey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20201255A1 publication Critical patent/PE20201255A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invencion se refiere a un anticuerpo que comprende una region variable de cadena pesada (VH) que comprende las secuencias de aminoacidos de SEQ ID NO: 6, 24, 32, 44, 51 o 64, la cual comprende tres regiones determinantes de complementariedad (CDR): (i) una CDR1 de VH que comprende la secuencia de aminoacidos de SEQ ID NO: 7, 33, 52 o 65; (ii) una CDR2 de VH que comprende la secuencia de aminoacidos de SEQ ID NO: 8, 25, 34, 45, 53 o 66; y (iii) una CDR3 de VH que comprende la secuencia de aminoacidos de SEQ ID NO: 9, 35, 46 o 47; y una region variable de cadena ligera (VL) que comprende las secuencias de aminoacidos de SEQ ID NO: 17, 28, 39, 48, 57 o 71, la cual comprende tres regiones determinantes de complementariedad (CDR): (i) una CDR1 de VL que comprende la secuencia de aminoacidos de SEQ ID NO: 18, 40, 58 o 72; (ii) una CDR2 de VL que comprende la secuencia de aminoacidos de SEQ ID NO: 19, 42, 60 o 74; y (iii) una CDR3 de VL que comprende la secuencia de aminoacidos de SEQ ID NO: 20, 42, 60, o 74. Tambien se refiere a un conjugado de anticuerpo, a una composicion farmaceutica, un polinucleotido que codifica el anticuerpo, un vector, una celula huesped y un metodo de produccion. Dicho anticuerpo se una especificamente a CD123, utiles en el tratamiento de una enfermedad autoinmune o cancer.
PE2020000682A 2017-10-27 2018-10-16 Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos PE20201255A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577922P 2017-10-27 2017-10-27
PCT/IB2018/058013 WO2019082020A1 (en) 2017-10-27 2018-10-16 ANTIBODIES AND CONJUGATES CD123-SPECIFIC ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
PE20201255A1 true PE20201255A1 (es) 2020-11-16

Family

ID=64109968

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000682A PE20201255A1 (es) 2017-10-27 2018-10-16 Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos

Country Status (17)

Country Link
US (2) US11613581B2 (es)
EP (1) EP3700929A1 (es)
JP (2) JP7324749B2 (es)
KR (1) KR102363746B1 (es)
CN (1) CN111556876A (es)
AU (1) AU2018357221A1 (es)
BR (1) BR112020008127A2 (es)
CA (2) CA3079788C (es)
CO (1) CO2020005347A2 (es)
IL (1) IL274095A (es)
MX (1) MX2020004381A (es)
PE (1) PE20201255A1 (es)
PH (1) PH12020550596A1 (es)
SG (1) SG11202003246WA (es)
TW (2) TWI718427B (es)
WO (1) WO2019082020A1 (es)
ZA (1) ZA202002207B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008127A2 (pt) 2017-10-27 2020-10-13 Pfizer Inc. anticorpos e conjugados de anticorpo-fármaco específicos para cd123 e seus usos
WO2021178597A1 (en) * 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
KR20240013732A (ko) * 2021-05-26 2024-01-30 옥스포드 바이오테라퓨틱스 리미티드 항-cd205 항체 및 면역 체크포인트 억제제를 포함하는 약학적 조합물
WO2023019393A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies, chimeric antigen receptors, and uses thereof
WO2023072934A1 (en) * 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2364484A1 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
HUE037651T2 (hu) 2011-04-20 2018-09-28 Medimmune Llc B7-Hl-et és PD-l-et kötõ ellenanyagok és más molekulák
ES2657014T3 (es) 2011-11-17 2018-03-01 Pfizer Inc. Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos
CA2919583C (en) 2013-07-31 2018-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
EP3134127B1 (en) 2014-04-25 2020-02-26 Rinat Neuroscience Corp. Antibody-drug conjugates with high drug loading
JP6805130B2 (ja) * 2014-09-05 2020-12-23 ヤンセン ファーマシューティカ エヌ．ベー． Ｃｄ１２３結合剤及びその使用
RS60916B1 (sr) * 2015-01-23 2020-11-30 Sanofi Sa Anti-cd3 antitela, anti-cd123 antitela i bispecifična antitela koja se specifično vezuju za cd3 i/ili cd123
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
PT3313884T (pt) * 2015-06-29 2021-02-25 Immunogen Inc Anticorpos anti-cd123 e conjugados e derivados dos mesmos
US20200165348A1 (en) * 2017-07-20 2020-05-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cd123-binding chimeric antigen receptors
BR112020008127A2 (pt) 2017-10-27 2020-10-13 Pfizer Inc. anticorpos e conjugados de anticorpo-fármaco específicos para cd123 e seus usos

Also Published As

Publication number Publication date
KR20200070361A (ko) 2020-06-17
JP2021500055A (ja) 2021-01-07
TW201922790A (zh) 2019-06-16
JP7324749B2 (ja) 2023-08-10
MX2020004381A (es) 2020-08-20
RU2020114487A3 (es) 2021-11-30
CO2020005347A2 (es) 2020-05-15
CA3205442A1 (en) 2019-05-02
TWI718427B (zh) 2021-02-11
CA3079788A1 (en) 2019-05-02
AU2018357221A1 (en) 2020-04-30
WO2019082020A1 (en) 2019-05-02
KR102363746B1 (ko) 2022-02-15
SG11202003246WA (en) 2020-05-28
TW202133881A (zh) 2021-09-16
PH12020550596A1 (en) 2021-02-15
RU2020114487A (ru) 2021-11-30
ZA202002207B (en) 2021-05-26
TWI793513B (zh) 2023-02-21
EP3700929A1 (en) 2020-09-02
CA3079788C (en) 2023-09-05
JP2023139267A (ja) 2023-10-03
BR112020008127A2 (pt) 2020-10-13
US11613581B2 (en) 2023-03-28
CN111556876A (zh) 2020-08-18
US20230357417A1 (en) 2023-11-09
US20200283536A1 (en) 2020-09-10
IL274095A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
HRP20201747T1 (hr) Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
HRP20210170T1 (hr) Protutijela protiv b7-h3 i konjugati protutijela s lijekom
CO2018013500A2 (es) Anticuerpos anti-pd-l1 y usos de los mismos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20191102A1 (es) Anticuerpos anti-pd-1 y sus usos
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
PE20110797A1 (es) Anticuerpos anti mn
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
AR109715A1 (es) Anticuerpos anti-cd27
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización